This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain VEEVA Systems (VEEV) Stock Now
by Zacks Equity Research
Investor confidence is high in VEEVA Systems (VEEV), thanks to solid prospects.
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Hexo's (HEXO) fiscal third-quarter results are likely to reflect operational efficiency and strong product portfolio.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.
Change Healthcare (CHNG) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across the Network Solutions segment and higher revenues.
Novartis' sBLA for Ofatumumab Gets Extended Review From FDA
by Zacks Equity Research
The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.
HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q1.
Zacks.com featured highlights include: Canadian Solar, Biogen, Graphic Packaging and Vistra Energy
by Zacks Equity Research
Zacks.com featured highlights include: Canadian Solar, Biogen, Graphic Packaging and Vistra Energy
Boost Portfolio Gains With These 6 Low Price-to-Book Stocks
by Kinjel Shah
Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.
AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.
Pick These 4 Low P/CF Stocks for a Value-Based Portfolio
by Sumit Singh
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
NextGen's (NXGN) fiscal fourth-quarter 2020 results gain from strong Recurring revenues.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
by Zacks Equity Research
With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.
Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.
Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia
by Zacks Equity Research
Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Top Analyst Reports for Alibaba, Chevron & Shopify
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Chevron (CVX) and Shopify (SHOP).
Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks.com
Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.
Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy
by Zacks Equity Research
Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy
Coronavirus Ruining Portfolio? Bet on These 4 Low P/CF Stocks
by Sumit Singh
Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.
Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA
by Zacks Equity Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
4 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.